Intravenous Immune Globulin Demonstration Fact Sheet (Demonstration Ends on December 31, 2023)
This revised Product comprises Subregulatory Guidance for Intravenous Immune Globulin Demonstration (IVIG), and its content is based on publically available content within at Medicare IVIG Access and Strengthening Medicare and Repaying Taxpayers Act of 2012 and IVIG demonstration website. CMS policy or operation subject matter experts also reviewed/cleared this product. This product educates on supplier eligibility and participation; patient eligibility and participation; and billing and coding requirements. Revisions to this Product include following content updates:
• Added information on Section 4134 of the CAA, 2023 (pages 1-7)
• Updated address for overnight mailings (page 4)
• Added 2024 payment rate for Q2052 (page 5)
• Added billing and coding information for IVIG items and services (pages 6 and 7)
The previous version of this product is available to the public and currently posted on the CMS website at https://www.cms.gov/files/document/intravenous-immune-globulin-demonstration.pdf.
Final
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: November 13, 2023
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.